Public Health

The National Council on Aging is spending the week of September 18th to the 22nd spreading awareness for falls prevention, and empowering older adults to educate themselves on how to be independent and falls free. This is a national effort to raise awareness, educate people on falls risk factors, and how to prevent falls. They are looking for support to encourage the engagement of older adults by starting a conversation with friends and family about falls. The National Council on Aging is also providing educational tools to help spread a better understanding of how falls are preventable.

The United Health Foundation recently released the 2023 Senior Report, an annual review of the health of the nation’s older adults and a critical tool to help guide individuals, community leaders, and policymakers to make decisions that are informed by reliable data. The report highlights successes and challenges older adults face in a broad range of health measures to help provide a portrait of the health and well-being of older adults throughout the United States. To accomplish this, the 2023 Senior Report collects data on many health measures, including race/ethnicity, gender, rural/urban geography, income, education, and more.

A KFF analysis estimates that life expectancy in the U.S. dropped 2.7 years between 2019 and 2021, from 78.8 years to 76.1 years, largely due to COVID-19 deaths. American Indian and Alaska Native (AIAN) people experienced the largest decline in life expectancy of 6.6 years during this time, followed by Hispanic and Black people (4.2 and 4.0 years, respectively). Also, provisional data for 2021 show that life expectancy was lowest for AIAN people at 65.2 years, followed by Black people, whose expectancy was 70.8 years, compared with 76.4 years for White people and 77.7 years for Hispanic people. It was highest for Asian people at 83.5 years...

Earlier this week University of Michigan’s Institute for Healthcare Policy and Innovation released findings from the University of Michigan National Poll on Health Aging. The new report share results gathered in late January 2023 that add to previous data from polls fielded in 2018 and during all three years of the COVID-19 pandemic. The report shared that one in three (34%) of older adults reported feeling isolated from others in the past year, a decline from the 2020 report findings.

On Monday, January 31st, CMS issued a final rule for the Medicare Advantage (MA) Risk Adjustment Data Validation (RADV) program. The MA RADV program is used to identify improper risk adjustment payments made to Medicare Advantage Organizations (MAOs) for claims made to Medicare without supporting evidence from a beneficiary’s medical record. Payments to MAOs are adjusted based on the health status of a MAO’s enrollees using medical diagnoses reported by the insurer. The new policy will apply to plan contracts since 2018.

The Centers for Disease Control and Prevention (CDC) released a fact sheet on how to protect older adults from Respiratory Syncytial Virus (RSV). RSV infections can be dangerous for older adults and those with chronic heart and lung disease, or those with weakened immune systems. The fact sheet reviews common symptoms, prevention methods, and more.

Paxlovid is an antiviral treatment for people with mild to moderate COVID-19 symptoms at high risk of becoming seriously ill, including adults 65 and up. It is important for older adults to consider a treatment plan before becoming infected, as Paxlovid could have complications with other drugs and should be evaluated by a medical provider. This article provides more information about Paxlovid and suggests ways older adults can prepare a treatment plan in advance of catching the new COVID-19 variant.

The FDA recently granted accelerated approval for the drug Leqembi, a medication intended to slow the progression of Alzheimer’s disease. Leqembi, the brand name for lecanemab, is the second Alzheimer’s therapy for individuals with mild cognitive impairment. Lequembi targets the protein amyloid and can be prescribed to patients in early to mid-stages of Alzheimer’s disease. Eisai, the manufacturer of Leqembi, reports that the drug will be available by January 23, 2023 and estimates the cost of the biweekly infusion to be $26,500 annually. Medicare coverage of Leqembi and other drugs like it, such as Aduhelm, that have accelerated FDA approval are limited to beneficiaries enrolled in certain clinical trials.

The Center for Health Care Strategies has released a summary of its top 10 resources from 2022 that outline opportunities to strengthen the U.S health care system, particularly for Medicaid beneficiaries.

The Center for Health Care Strategies, with support from the New York Health Foundation and in partnership with ATW Health Solutions, assisted seven New York-based health care organizations in piloting strategies for engaging patients of color to advance health equity. This CHCS brief outlines considerations for health care organizations in developing patient engagement strategies, including: (1) building trust with patient partners over time; (2) tailoring outreach strategies; (3) using-trauma-informed approaches; (4) engaging patients in data use; and (5) approaching engagement with humility.